Topic
Benzopyrans
About: Benzopyrans is a research topic. Over the lifetime, 694 publications have been published within this topic receiving 8830 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: Heterodiene cycloadditions of 4-oxo-4H-1-benzopyrans with formyl, acetyl, or carboxyl substituents at C-3 to 1-alkoxy- or 1,1-dialkoxyalkenes produce 3-alkiox- or 3,3-dialknoxy-4,4a- dihydropyrano[4,3b][1]benzopsopyran-10-ones which are capable of a variety of selective transformations, including acid-induced epimer
Abstract: Heterodiene cycloadditions of 4-oxo-4H-1-benzopyrans with formyl, acetyl, or carboxyl substituents at C-3 to 1-alkoxy- or 1,1-dialkoxyalkenes produce 3-alkoxy- or 3,3-dialkoxy-4,4a- dihydropyrano[4,3-b][1]benzopyran-10-ones which are capable of a variety of selective transformations, including acid-induced epimerisation and/or retro-cycloaddition, reduction, hydrolysis and alcoholysis, in some cases under very mild conditions.
2 citations
2 citations
2 citations
Journal Article•
TL;DR: The title compounds were synthesised by the condensation of ethyl alpha-propyl/isopropyl/n-butylacetoacetate (13-15) with disubstituted phenols (1-12) in presence of POCL3 or 73 percent H2SO4 as mentioned in this paper.
Abstract: The title compounds were synthesised by the condensation of ethyl alpha-propyl/isopropyl/n-butylacetoacetate (13-15) with disubstituted phenols (1-12) in presence of POCL3 or 73 percent H2SO4. Compounds 25, 27 and 39 prevented in vitro clotting of blood for 40, 120 and 30 min. respectively. In gross behavioural effects, compound 35 was found to be depressant while 36-38 were stimulants. Rest of the compounds did not show any significant activity.
2 citations
Patent•
20 Jul 1990
TL;DR: In this paper, the present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Y, R 2, R 3, R 4, R 5, R 6, R 7, a and b are as defined in the Specification, having pharmacological activity, to a process for their preparation, and to their use as pharmaceuticals.
Abstract: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein Y, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , a and b are as defined in the Specification, having pharmacological activity, to a process for their preparation, and to their use as pharmaceuticals.
2 citations